Patent application number | Description | Published |
20080241210 | WOUND HEALING AGENT AND COMPOSITION - The present invention relates to a wound-treating agent and to a composition for the treatment of wounds comprising a polypeptide having the amino acid sequence of SEQ ID NO:2, or of a polypeptide having at least 50%, preferably 70%, more preferably 90% identity with the amino acid sequence of SEQ ID NO:2. | 10-02-2008 |
20080254145 | Anti-tumor drug, medicament, composition, and use thereof - The present invention relates to an active polypeptide comprising the amino acid sequence of SEQ ID NO:3, or having at least 50%, preferably 70%, more preferably 90% identity with the amino acid sequence of SEQ ID NO:3, or fragments thereof having at least 21 contiguous amino acids, or peptides having at least 50%, preferably 70%, more preferably 90% identity with the amino acid sequence of the fragments, provided that the polypeptide is not SEQ ID NO:2. | 10-16-2008 |
20080286381 | Anti-tumor drug, medicament, composition, and use thereof - An active polypeptide includes the amino acid sequence of SEQ ID NO:3, or having at least 50%, preferably 70%, more preferably 90% identity with the amino acid sequence of SEQ ID NO:3, or fragments thereof having at least 20 contiguous amino acids, or peptides having at least 50%, preferably 70%, more preferably 90% identity with the amino acid sequence of the fragments, provided that the polypeptide is not SEQ ID NO:2. | 11-20-2008 |
20090264364 | GENES IMPLICATED IN THE REGULATION OF ANGIOGENESIS, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR APPLICATIONS - Therapeutic compositions used in the field of angiogenesis include nucleotide sequences of genes, the involvement of the genes in the angiogenesis mechanism having been demonstrated by the Applicant, and including the complementary sequences thereof, the antisense sequences of same, polypeptide sequences coded by the coding parts of the aforementioned genes and antibodies that are directed against the polypeptide sequences and also relate to genetically-modified cells that underexpress or overexpress the above-mentioned genes and to therapeutic compositions containing the cells, which are used to treat angiogenic disorders, and, moreover, relate to methods of diagnosing and/or prognosticating antigenic disorders and to novel methods of screening active compounds in the treatment of the disorders. | 10-22-2009 |
20100047369 | ANTI-TUMOR DRUG, MEDICAMENT, COMPOSITION, AND USE THEREOF - An active polypeptide comprising the amino acid sequence of SEQ ID NO: 3, or having at least 50%, preferably 70%, more preferably 90% identity with the amino acid sequence of SEQ ID NO: 3, or fragments thereof having at least 21 contiguous amino acids, or peptides having at least 50%, preferably 70%, more preferably 90% identity with the amino acid sequence of the fragments, provided that the polypeptide is not SEQ ID NO: 2. A method for inhibiting cancer and/or tumour growth comprising administering to a subject in need thereof an effective amount of the active polypeptide. | 02-25-2010 |
20100135985 | Genes involved in the regulation of angiogenesis, pharmaceutical preparations containing them an uses thereof - The invention pertains to the area of pharmaceutical compositions that are useful for treating pathologies resulting from a deregulation of the angiogenesis mechanism. The invention particularly concerns new genes whose function had not been identified before now as well as genes that are known but whose involvement in the angiogenesis mechanism has been shown for the first time. | 06-03-2010 |
20100151051 | ANTI-TUMOR DRUG, MEDICAMENT, COMPOSITION, AND USE THEREOF - An active polypeptide comprising the amino acid sequence of SEQ ID NO:4, having an anti-tumour activity, and compositions and methods including the active polypeptide. | 06-17-2010 |
20110038951 | ANTI-TUMOR DRUG, MEDICAMENT, COMPOSITION, AND USE THEREOF - The present invention relates to an active polypeptide including the amino acid sequence of SEQ ID NO:3, or having at least 50%, preferably 70%, more preferably 90% identity with the amino acid sequence of SEQ ID NO:3, or fragments thereof having at least 21 contiguous amino acids, or peptides having at least 50%, preferably 70%, more preferably 90% identity with the amino acid sequence of the fragments, provided that the polypeptide is not SEQ ID NO:2, variants and antigenic fragments thereof, SEQ ID NO 16 or SEQ ID NO 17. | 02-17-2011 |
20110104169 | REGULATOR GENES OF ANGIOGENESIS, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR APPLICATIONS - Nucleotide sequences and the corresponding polypeptide sequences implicated in the regulation of angiogenesis are identified. The nucleotide and polypeptide sequences, or pharmaceutical composition made from such sequences can be used in the clinical study of the angiogenesis process, the prognosis, diagnosis and treatment of pathologies linked to angiogenesis, and in the implementation of pharmaceutical, pharmacogenomic and drug identification trials. | 05-05-2011 |
20110306545 | NOVEL PEPTIDES FOR WOUND HEALING - The present invention relates to new peptides, pharmaceutical composition and cosmetic composition including them and their use for wound healing. | 12-15-2011 |
20120041047 | Injectable Pharmaceutical Composition for Preventing, Stabilizing and/or Inhibiting Pathological Neovascularization-Related Conditions - This invention relates to a pharmaceutical composition for the treatment and/or prevention of at least one pathological neovascularization-related conditions of the interior of the eye, the composition comprising a therapeutically effective amount of an antisense oligonucleotide having the sequence SEQ ID NO: 1: | 02-16-2012 |
20120157389 | PEPTIDES FOR TREATING CANCER - The present invention relates to peptide from 4 to 50 amino acids comprising a phosphorylated pYX | 06-21-2012 |
20130004511 | COMPOSITION COMPRISING INHIBITORS OF IRS-1 AND OF VEGF - Compositions comprising an inhibitor of IRS-1 and an inhibitor of the VEGF pathway, which compositions rare useful for treating an angiogenic disease. The specification also relates to kits comprising an inhibitor of IRS-1 and an inhibitor of the VEGF pathway, as well as methods of treating angiogenic diseases using such compositions and/or kits. | 01-03-2013 |
20130143947 | Injectable Pharmaceutical Composition for Preventing, Stabilising and/or Inhibiting Pathological Neovascularization-Related Conditions - This invention relates to a pharmaceutical composition for the treatment and/or prevention of at least one pathological neovascularization-related conditions of the interior of the eye, the composition comprising a therapeutically effective amount of an antisens oligonucleotide having the sequence SEQ ID NO: 1: 5′-TCTCCGGAGGGCTCGCCATGCTGCT-3′ or any function conservative sequence comprising from 9 to 30 nucleotides that has 75%, 80%, 85%, 90%, 95% or more than 95%, 96%, 97%, 98%, 99% of identity compared to SEQ ID NO: 1 and that conserves the capacity of inhibiting IRS-1 gene expression as SEQ ID NO: 1, and the composition being administered within the posterior segment of the eye to a subject in need thereof; this invention also relates to a method for treating a pathological neovascularization-related condition of the interior of the eye in a subject in need thereof comprising administering to the subject a therapeutically effective amount of said pharmaceutical composition. | 06-06-2013 |
20130157949 | Novel Peptides for Wound Healing - The present invention relates to new peptides, pharmaceutical composition and cosmetic composition comprising them and their use for wound healing. | 06-20-2013 |
20130274202 | Peptides for Treating Cancer - The present invention relates to peptide from 4 to 50 amino acids comprising a phosphorylated pYX | 10-17-2013 |
20140011858 | Inhibitor of IRS-1 for Treating Skin Disorders - The present invention relates to an inhibitor of the expression of IRS-1 for treating an angiogenic and/or inflammatory skin disease. The present invention also relates to a transdermal composition, preferably an ointment, comprising an inhibitor of the expression of IRS-1, and to the use thereof for treating an angiogenic and/or inflammatory skin disease. | 01-09-2014 |
20140134185 | Composition Comprising Inhibitors of IRS-1 and of VEGF - The present invention relates to a composition or kit of parts comprising an inhibitor of IRS-1 and an inhibitor of the VEGF pathway and to the use thereof for treating an angiogenic disease. | 05-15-2014 |
20140134276 | ANTI-TUMOR DRUG, MEDICAMENT, COMPOSITION, AND USE THEREOF - A method for the treatment of cancers and/or tumors by administration of a polypeptide having the sequence SEQ ID NO:4 or a polypeptide having an amino acid SEQ ID NO Y which, when aligned with SEQ ID N: 4, has (a) a percentage of identical residues over SEQ ID NO: 4 length of at least 50%, and (b) a percentage of identical residues over a amino acid sequence SEQ ID NO Y length of at least 65% or fragments thereof having at least 20 contiguous amino acids. | 05-15-2014 |